On July 2, Abivax S.A. rose 6.37% overnight, trading at 141.0 USD/share, with turnover of approximately $415,600.

On the news front, the company completed the pricing of an underwritten public offering of 6.4 million American Depositary Shares at $125 each, totaling $800 million — upsized from an initially announced $600 million, signaling robust institutional subscription demand. Proceeds will primarily fund the potential commercialization of lead drug candidate obefazimod in the United States, as well as clinical development for ulcerative colitis and Crohn's disease.

The upsizing follows a sharp rebound of over 38% after the company reported positive ABTECT Maintenance Part 2 data on June 30, which showed no new safety signals and effectively addressed prior concerns over malignancy cases in the 50 mg cohort. The stock continues to trade well above the $125 offering price, reflecting sustained market confidence in the company's near-term FDA submission plans and commercial outlook.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)